Fresh off the world’s largest mammalian longevity screen, Longevica names ex-Genentech exec Prasun Mishra to steer science toward the clinic.
Longevica Therapeutics has spent the past four years and $13 million running mice through their entire lives to find drugs that might extend ours. Now, with that screening program wrapped, the company has hired someone whose job is to turn a mouse dataset into something a regulator will actually approve.
The preclinical biotech announced that Dr Prasun Mishra will take over as CEO and join its board [1]. Mishra’s résumé reads like a checklist for exactly this moment: stints at Genentech, Roche, the National Institutes of Health, the National Cancer Institute, UCSF and Rutgers, plus a track record of shepherding more than 30 therapeutic programs – 12 of which reached clinical trials and four of which won regulatory approval.
The company’s pitch rests on a single, expensive bet: that most aging research has been done in the wrong animals. Worms and fruit flies are cheap and fast, but they don’t have organs that talk to each other across years the way ours do. So Longevica went the other direction – an in vivo screen, in mammals, run to completion.
Working with The Jackson Laboratory, the company tested 1,033 small-molecule compounds across more than 16,000 mice, following each cohort from adulthood through natural death. That’s the part that makes the dataset unusual: it isn’t a snapshot or a short-term readout, but a full record of which compounds changed how long the animals lived.
Digging through that data, Longevica says its scientists have identified two previously uncharacterized biological mechanisms tied to mammalian lifespan extension – new leads that didn’t exist in the literature before this screen produced them.
From mouse data to a drug pipeline
Having a pile of longevity data is one thing. Turning it into a drug that clears the FDA is another entirely, and it’s the part of the industry where good geroscience has historically stalled out. That’s the gap Mishra is being brought in to close.
“The central challenge in geroscience is no longer simply establishing that aging biology is modifiable, but determining which mammalian mechanisms can be translated into disease-modifying prescription therapeutics,” Mishra said.
Mishra explained that while much of the field is limited to academic observations or computational modeling, Longevica generated concrete, full-lifespan in vivo data across more than 1,000 small molecules in a mammalian system. He emphasized that the company’s clear strategic focus is to apply biopharmaceutical discipline to convert these empirical targets into first-in-class therapeutics, advance lead programs through IND-enabling studies, and establish high-value strategic alliances across the global biopharmaceutical industry.
Longevica’s founder and chairman, Alexander Chikunov, put the hire in the context of an industry-wide problem.
“Over the past decade, the longevity sector has faced a fundamental translational validation challenge. The industry frequently attempted to build clinical pipelines on retrospective data mining, short-lived lower organisms, or reductionist cell assays that fail to reflect mammalian physiology,” Chikunov said. “Longevica chose to address that challenge at the source by investing four years and $13 million to build an empirical, full-lifespan dataset at The Jackson Laboratory.”
Chikunov said that, with candidate mechanisms identified and foundational intellectual property already issued, Mishra’s proven track record of guiding complex programs from preclinical discovery through IND filings and regulatory approvals makes him the ideal executive to lead Longevica’s commercial translation.
Three things happening at once
The company says it’s now running three tracks in parallel: pushing its lead candidates – initially aimed at age-related metabolic dysfunction and fibrotic disease – into the formal preclinical studies required before human trials can start; layering machine learning onto the Jackson Laboratory dataset to squeeze more targets and refine existing compounds; and courting pharmaceutical partners for co-development deals. All of these while also eyeing a faster side door through veterinary medicine, where companion animals age through similar disease processes on a compressed timeline.
That veterinary angle is worth pausing on. Human drug approval can take a decade or more. A therapy tested in dogs or cats, whose lifespans are a fraction of ours, could show real-world results (and generate revenue) well before any human trial reads out.
Longevica’s story is really the longevity field’s story in miniature: an industry that has gotten very good at describing what aging looks like at a cellular level, and much less good at turning that description into something a pharmacist can hand you.
Hiring an executive whose actual job history is getting drugs through the FDA, rather than publishing about the biology of aging, is a signal about where the company thinks the bottleneck really sits: in the unglamorous business of proving it works in humans, one regulatory filing at a time.
